Table 4 RMST ratio between low- and high-risk groups based on immune risk score or immune clinical score in training, validation dataset-1 and validation dataset-2
From: An individualized immune prognostic signature in lung adenocarcinoma
RMST (years) | Immune risk score | Immune clinical score | ||||
|---|---|---|---|---|---|---|
Low risk (95% CI) | High risk (95% CI) | Ratio (95% CI) | Low risk (95% CI) | High risk (95% CI) | Ratio (95% CI) | |
Training dataset | 8.01 (7.62–8.40) | 5.45 (4.91–5.99) | 1.47 (1.32–1.64) | 8.66 (8.27–9.04) | 5.55 (5.09–6.02) | 1.56 (1.42–1.71) |
Validation dataset-1 | 6.34 (5.87–6.83) | 5.05 (4.49–5.62) | 1.26 (1.10–1.44) | 6.46 (6.06–6.87) | 3.25 (2.56–3.93) | 1.99 (1.60–2.48) |
Validation dataset-2 | 3.29 (3.13–3.45) | 2.85 (2.59–3.11) | 1.16 (1.04–1.28) | 3.36 (3.22–3.51) | 2.60 (2.32–2.90) | 1.29 (1.15–1.46) |